On October 19th, the 2023 China Biotechnology Innovation Conference, a national event in the Chinese biopharmaceutical industry, opened in the Chengdu High tech Zone. 27 academicians, over 300 heavyweight experts, over 1000 experts and scholars, nearly 20 Fortune 500 multinational pharmaceutical companies, and more than 50 well-known domestic and foreign pharmaceutical enterprises have gathered in Chengdu to jointly seek innovative development in the pharmaceutical and health industry.
It is reported that the theme of this conference is "high-level innovation and high-quality development", co hosted by the China Biotechnology Development Center and the Chengdu Municipal People's Government, and organized by the Chengdu High tech Zone Management Committee. It will further promote the integration, innovation, and exchange cooperation in the field of biotechnology.
27 academicians gathered in Rongcheng
Provide suggestions and suggestions for the development of the biopharmaceutical industry
The conference attracted 27 academicians, including Deng Zixin, academician of the CAS Member, Zhang Xingdong, academician of the CAS Member, Yu Junchong, academician of the CAE Member, and Zhang Xuemin, academician of the CAS Member. In addition, 20 Fortune Global 500 multinational pharmaceutical companies, including AstraZeneca, Bayer, GSK, and Aberdeen, as well as more than 50 well-known domestic and foreign pharmaceutical companies, have also gathered in Chengdu to discuss the innovation and development of biotechnology.
At the opening ceremony of the conference, the three academicians shared theme reports from different perspectives, and together with the attending guests, discussed the latest cutting-edge in the field of biotechnology and looked forward to future development trends.
Around the theme of "innovation and clinical transformation of immunotherapy", Dong Chen, an academician of the CAS Member, delivered a thematic report, introducing in detail the core elements of immune regulation and immune response, as well as the progress of T cells in the treatment of inflammatory diseases and tumor immunotherapy, and sharing the cutting-edge information of immunology and immunotherapy.
"New technology progress in vaccine research and development" is a hot topic in the field of public health. Wei Yuquan, an academician of the CAS Member, focused on the above topics to carry out a report, introduced in detail the research and development, large-scale production and industrialization of recombinant COVID-19 vaccine, and shared the history of COVID-19 vaccine research and development.
In view of the main development trend of food in the future, Chen Jian, academician of the CAE Member, made a theme report entitled "Developing Future Food Based on Biological Manufacturing", introducing in detail the biotechnology closely related to the food biotechnology industry, and sharing the future development prospects of the food industry.
In addition, at the opening ceremony on the same day, four authoritative new medical reports, namely "2023 China Life Sciences and Biotechnology Development Report", "2023 China Clinical Medicine Research and Development Report", "2023 China Medical Device Technology Innovation and Development Report - Biomedical Materials", and "2022 Traditional Chinese Medicine Development Report", were officially released, edited by the China Biotechnology Development Center. They cover biological science research, clinical medicine research and development Summarized and introduced future development trends in fields such as biopharmaceutical materials and traditional Chinese medicine, providing academic support for industry development.
Set up 16 branch meetings and 3 thematic side meetings
Collaborate on high-quality development of biotechnology
The conference focuses on professional fields such as synthetic biology, cell and gene therapy, and nuclide drugs, with 16 sessions set up. Compared with previous sessions, the content and theme of this session are more detailed, with full attention.
Among them, around the theme of innovation breakthrough and strategic layout for pharmaceutical and mechanical enterprises, the Enterprise Innovation Branch gathered more than 10 Fortune Global 500 enterprises such as Bayer, GE, Roche, AZ, and MSD, as well as more than 90 national industrial and innovative enterprises such as Qilu Pharmaceutical and Lianying Medical, to share and exchange ideas, explore new models and opportunities for domestic and foreign pharmaceutical and mechanical innovation cooperation. The Youth Talent Branch invited more than 10 young scientists from the Ministry of Science and Technology to participate in the conference and released the second batch of projects for the Global Youth Talent Resource Plan of Tianfu Jincheng Laboratory (Frontier Medical Center). The Financial Capital Branch invited the top 50 companies in the biopharmaceutical field, such as Junlian Capital, as well as relevant leaders of well-known domestic and foreign investment institutions, to give a themed report and release a list of scientific and technological achievements roadshow projects.
In addition, the conference also set up three special side meetings, including a closed door seminar on experimental animal resources and the Chengdu Chongqing Shuangcheng Economic Circle.
Among them, the theme of the Chengdu Chongqing Shuangcheng Economic Circle will focus on major strategies such as the Shuangcheng Economic Circle, promote the docking of key core technology industry demand, and promote the signing of cooperation projects between Olin Biotech and Chongqing Third Military Medical University, Biotech and Meilaide, as well as the signing of contracts between Biotech City, Marine Science Center, and Chengdu Customs. We will conduct comprehensive and in-depth cooperation around customs application technology and standardization system construction research, Injecting innovative momentum into the construction of the Chengdu Chongqing dual city economic circle.
The innovation vitality of the biological industry continues to burst out
Continuously enhancing collaborative innovation capabilities
At the opening ceremony, the "2023 China Biopharmaceutical Industry Park Development Status Analysis Report" (hereinafter referred to as the "Report") was officially released, and the report released the 2022 China Biopharmaceutical Park Competitiveness Ranking.
It is reported that the rankings are divided into comprehensive competitiveness and individual competitiveness rankings. After sorting out the rankings, it was found that the award-winning cities were all advantageous in China's biotechnology development. For example, in the comprehensive competitiveness rankings, Chengdu High tech Zone, Zhongguancun National Independent Innovation Demonstration Zone, Suzhou Industrial Park, and Shanghai Zhangjiang High tech Industrial Development Zone ranked first.
As a highland for the development of biotechnology in Chengdu, recently, Rongsheng Pharmaceutical Co., Ltd., a high-tech zone enterprise in Chengdu, independently developed and produced "Recombinant Human Coagulation Factor VIII for Injection" and the fourth generation "Intravenous Human Immunoglobulin (pH4)", which have been approved by the National Drug Administration and will soon be listed.
It is reported that Chengdu Rongsheng Pharmaceutical has completed the construction of the blood product industry base in the Biocity and has successfully put it into production and operation. At the same time, the recombinant coagulation factor workshop has also been completed and officially put into operation. The company will become the first production base in Asia to produce fourth generation immunoglobulins and the world's first production base that can simultaneously produce blood products and genetic engineering recombinant products.
The reporter learned that this is only a microcosm of the continuous burst of innovation vitality in the biological industry of Chengdu High tech Zone. As the main battlefield for the development of Chengdu's industry, the Chengdu High tech Zone actively attracts top talents and high-end scientific and technological innovation platforms, promotes the rapid growth of innovative varieties in enterprises, strengthens international cooperation in innovative varieties, and establishes a joint laboratory for vaccine development with the University of Griffith in Australia. The joint development of Class 1 innovative vaccine, Group A streptococcal vaccine, is about to apply for clinical trials of new drugs; Konoya and AstraZeneca have reached an exclusive global licensing agreement for the antibody conjugated drug CMG901, with a selling price of 1.2 billion US dollars, which is the second highest selling price for this target in China
The relevant person in charge of Chengdu High tech Zone stated that in the next step, Chengdu High tech Zone will aim at the future track of the biological industry, accelerate the pace of talent introduction and innovative variety research and development, promote the collaborative innovation development of the industrial chain, and accelerate the construction of a modern medical and health industry system with international competitiveness and regional driving force.